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Objective: To explore the functional significance of in-
cident neuropsychologic impairment among initially
asymptomatic subjects infected with human immuno-
deficiency virus.
Design: Prospective, observational cohort study of ho-
mosexual and bisexual men to examine the incidence of
work disability related to the onset of neuropsychologic
impairment.
Setting: A university clinical and behavioral research
site in New York City.
Participants: Sample of 207 homosexual and bisexual
men; 123 were seropositive and 84 were seronegative.
Principal Outcome Measures: Incident work disabil-
ity in the course of 4.5 years of follow-up, with disabil-
ity defined as a persistent (\m=ge\24months) change in work
hours (from 20 or more to less than 20 h/wk).
Results: Compared with seronegative control subjects(n=72), the relative risk of work disability among ini-
tiallyasymptomatic seropositive men (n=44) was 2.76 (95%
confidence interval, 1.2 to 6.5), nearly a threefold in-
crease. Proportional hazards models show that this in-
creased risk is attributable to the development of major
neuropsychologic impairment in a subset (eight of 44) of
the initially asymptomatic men, which is significantly as-
sociated with incident work disability (6/8 [75%]). Ad-justing for symptom status and CD4+ cell count at the time
of disability did not eliminate the increased risk associ-
ated with neuropsychologic impairment.
Conclusions: In this cohort, the increased risk of work
disability among initially asymptomatic human immu-
nodeficiency virus\p=m-\positivemen was related to incident
neuropsychologic impairment; such impairment pre-
dicted work disability independently of symptom status
and CD4+ cell count over the follow-up period. Neuro-
psychologic impairment in the course of human immu-
nodeficiency virus infection may indicate increased risk
for poor outcomes over and above that associated with
systemic disease.
(Arch Neurol. 1995;52:525-530)
While neuropsycho¬logic impairment inasymptomatic hu¬man immunodefi¬ciency virus (HIV)
infection has not been universally
reported,1"9 abnormal neuropsychologic
performance may represent an indepen¬
dent source of morbidity and mortality
in the progression of HIV infection. In
one study,10 the presence of neuropsy¬
chologic impairment in seropositive(HIV + ) individuals at baseline signifi¬
cantly increased the risk of mortality in 3
years of follow-up, even after adjusting
for the progressive immunologie and sys¬
temic effects of HIV.
Neuropsychologic deficit in asymp¬
tomatic HIV disease was singled out for re¬
search because it is likely to have impor¬
tant functional consequences. Deficits in
memory, attention, retrieval of informa¬
tion, and planning, for example, are likely
to interfere with performance of daily tasks.
For the patient infected with HIV who is
otherwise physically asymptomatic, these
deficits may result in significant morbid¬
ity, in the sense that patients may be un¬
able to perform important tasks (eg, driv¬
ing, work tasks), or may voluntarily
withdraw from such activities because of
concerns that they will be unable to per¬
form them competently. Because medical
care and drug therapies have allowed pa¬
tients with HIV infection to live longer, HIV
has become less an acute disease than a
chronic one, in which morbidities of this
sort must be addressed for the important
goal of tertiary prevention, ie, prevention
of excess disability.
See Subjects and Methods
on next page
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SUBfECTS AND METHODS
SUBJECTS
The sample for this investigation included 207 homo¬
sexual and bisexual men (123 seropositive and 84 sero¬
negative), the first of whom were enrolled in 1988. Sub¬jects were enrolled through advertisements placed in
newspapers with a homosexual clientele and in sites fre¬
quented by homosexual and bisexual men. To be eli¬
gible, subjects had to know their serostatus (owing to
sensitivity regarding the acquired immunodeficiency
syndrome [AIDS] research at the time) and not yet meet
the clinical criteria for AIDS (because the research
focused particularly on the natural history of HIV infec¬
tion). Complete information regarding recruitment and
study design for this "Columbia cohort" has been
reported elsewhere." Baseline analyses of the cohort
with regard to neuropsychologic performance,3 psychiat¬
ric diagnoses,12 and behavioral risk factors for HIV infec¬
tion13 have also appeared.
ASSESSMENTS
After giving informed consent, subjects were examined at
6-month intervals, at which time a full medical examina¬
tion, neurologic and neuropsychologic examination, psy¬
chiatric examination, laboratory assessment of immuno¬
logie function, and behavioral survey were undertaken. All
examinations were performed by physicians and research
staff who were shielded from the HIV status of subjects.
DETERMINATION OF HIV SYMPTOM STATUS
Based on the examination and medical history, symptoms
related to HIV were scored using the HIV Center Medical
Staging Scale.14 In this scale, subjects with scores of 9 or
less are considered physically asymptomatic; any symp¬
toms reported are unrelated to HIV infection and are not
severe enough to warrant clinical attention. A score of 10
through 19 indicates minimal HIV-related symptoms, such
as generalized lymphadenopathy. A score of 20 through 29
indicates moderate symptomatic status, with serious con¬
stitutional symptoms. Scores of 30 or greater indicate that
a subject meets the criteria for AIDS as defined by the Cen¬
ters for Disease Control and Prevention (Atlanta, Ga). Sub¬




An extensive battery of neuropsychologic tests was admin¬
istered to the cohort and is described in detail elsewhere.3
Individual tests were grouped into areas of cognitive func¬
tion, ie, general mental status, memory, language ability,
executive function, visuospatial function, attention, and mo¬
tor speed/praxis. Performance on each test was compared
with norms derived from populations of the same age and
education, allowing test scores to be considered normal,
borderline (at least 1 SD below the mean), or defective (at
least 2 SDs below the mean). Subjects were assigned a
"global neuropsychologic performance score" of 0 (no per¬
formance deficit in any cognitive area), 1 (borderline per¬
formance in two or more areas), 2 (defective performance
in one area), 3 (defective performance in two or more ar¬
eas), or 4 (defective performance in memory and in two
or more areas). For this analysis, neuropsychologic per¬
formance was considered to be defective if subjects scored
3 or greater, ie, test scores were in the defective range for
two or more areas of cognitive function.
In addition to neuropsychologic testing, subjects were
rated on neurologic symptoms, including cognitive and mo¬
tor symptoms,3 and on a modified expanded disability sta¬
tus scale, which served as a global neurologic perfor¬
mance score.15
DETERMINATION OF WORK DISABILITY
At each assessment, subjects were asked about their
employment status, which was coded as full-time, full-
time but limited in vocational function, not fully
employed but half-time or more, between half-time and
quarter-time, quarter-time or less, and not working. For
this analysis, these scores were dichotomized, so that
subjects working half-time or more (ie, &20 h/wk) were
considered fully employed. This dichotomy seemed
appropriate because a number of subjects in the cohort
were self-employed and set their own hours. It is in any
case a conservative approach to work disability, as it
requires subjects to reduce their work time considerably
before they are considered disabled.
As an additional constraint, subjects were considered
to have experienced work disability only if they remained
at less than half-time employment for 2 or more years. Sub¬jects who reported less than half-time employment at one
visit, but who reported more than half-time employment
in the next assessment, were not considered in terms ofwork
disability.
DATA ANALYSES
Time to onset of work disability and cumulative inci¬
dence of work disability were assessed using product-
limit life-table analyses"1 and proportional hazards
regression models,17 implemented in the Statistical
Analysis System. Both methods treat work disability as
an end point and adjust for subjects who were not avail¬
able for follow-up (ie, censoring). The primary analytic
approach is to compare subjects who were seronegative
or asymptomatic seropositive at baseline according to
the cumulative incidence of work disability and to assess
covariates that increase the risk of work disability. Pro¬
portional hazards models offer the advantage of using
both baseline and time-dependent covariates in predict¬
ing onset of work disability.
These survival models generate risk ratios (or rela¬
tive risks [RRs]) that specify the degree to which risk of
work disability is elevated, relative to a reference group,
given that a subject has certain baseline characteristics or
other characteristics that appear in the course of follow-
up. The SE associated with this RR is used to generate con¬
fidence intervals (Cls) for assessing the significance of any
particular covariate, net of other covariates, in predicting
work disability.
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To examine the functionalsignificance of cognitive
impairment in early HIV infection, we analyzed a cohort
of asymptomatic seropositive individuals compared with
a seronegative control group and determined the effect of
incident neuropsychologic impairment on employment,
a central component of everyday life. Work disability of¬
fers an excellent test of the functional significance of neu¬
ropsychologic deficit. Examining incident work disabil¬
ity among initially asymptomatic seropositive subjects may
give a clearer picture of the functional significance of emerg¬
ing defects in neuropsychologic performance related to HIV
infection.
RESULTS
The number of subjects followed up in this natural his¬
tory study and attrition in the cohort over the 10 assess¬
ments are shown in Table I. The table also shows the
percentage of seropositive subjects at each assessment.
As part of the inclusion criteria for the study, no subject
had AIDS at baseline. Only one subject seroconverted,
and this occurred in year 5 of the study. At 54 months(visit 10), about half the cohort was not available for fol¬
low-up. There were 34 known deaths, a likely underes¬
timate, since analyses show that sicker subjects were more
likely to be unavailable for follow-up. However, unavail¬
ability for follow-up did not differ between seronegative
subjects and subjects who were asymptomatic at base¬
line, the groups of primary interest in the analysis.
We first examined the extent to which baseline symp¬
tom status was associated with incident work disability.
Eliminating subjects who were not fully employed at base¬
line left a sample of f 85 subjects, who formed the risk
set for this survival analysis. Table 2 shows the break¬
down of the full set of subjects by medical stage, the cu¬
mulative incidence of work disability for each group of
subjects, and the RR associated with HIV medical stage,
using the seronegative subjects as a reference group.
While the cumulative incidence of work disability in
the seronegative group was 16%, it was 40% in the asymp¬
tomatic group, 53% in the minimally symptomatic group,
and 48% in the moderately symptomatic group. Relative
to the seronegative group, each of the HIV+ baseline symp¬
tom groups had a significantly elevated risk of work dis¬
ability over the course of the follow-up period. The asymp¬
tomatic group was nearly three times more likely to
experience work disability than was the seronegative
reference group (RR, 2.76; 95% CI, 1.2 to 6.5).
A first attempt to determine the sources of this el¬
evated risk for incident work disability is shown in Table 3,
which compares seronegative and HIV+ asymptomatic
subjects on baseline characteristics. The HIV+ asymp¬
tomatic group had a poorer immune profile and poorer
neurologic symptom rating, but the groups did not differ
significantly on any other parameter, including educa¬
tion, social class, disability rating, motor or cognitive func¬
tion, or mean score on the global measure of neuropsy¬
chologic performance (though the two groups do differ
in raw score performance on a number of the tests, as re¬
ported by Stern et al3). As depression and substance abuse
disorders might also be confounded with HIV status and
risk of incident work disability, these also were investi¬
gated. As shown in Table 3, the groups were comparable
in the proportion of subjects with syndromal depressive
disorders and substance abuse diagnoses (as established
by the criteria of the Diagnostic and Statistical Manual of
Mental Disorders, Revised Third Edition18).
Entering the baseline characteristics that distin¬
guished the groups as covariates in a proportional haz¬
ards model did not yield significant predictors of work
disability. For example, the RR for baseline CD4+ cells
was not significant in a model that also included HIV sta¬
tus. Similarly, neurologic rating was not a significant pre¬
dictor of work disability independent of HIV status.
Because baseline covariates did not predict time to
onset of work disability, time-dependent covariates were
introduced. We were particularly interested in assess¬
ing the role of incident neuropsychologic deficit in the
asymptomatic HIV+ group as a potential source of work
disability, given results from prior research.10 We used
the measure of defective neuropsychologic perfor¬
mance described above, ie, test scores in the defective
range in at least two areas of cognitive function, as a time-
dependent covariate. The time-dependent approach as¬
sesses the relationship between defective neuropsycho¬
logic performance at each assessment and incident work
Table 2. Cumulative Incidence of Work Disability by Baseline HIV Medical Stage4
Stage  Cumulative Incidence Censored, % Beta Estimate RR 95% CI
HIV- 72 0.16 0.89
...
1.00
Asymptomatic HIV+ 44 0.40 0.66 1.017 2.76 1.2-6.5
Minimally symptomatic HIV+ 28 0.53 0.54 1.399 4.05 1.6-9.8
Moderately symptomatic HIV+ 41 0.48 0.68 1.112 3.04 1.3-7.4
* Seronegative respondents serve as reference group. Human immunodeficiency virus (HIV) medical stage defined according to Columbia University HIV
Center Medical Staging Scale (Gorman et al'4): asymptomatic, minimally symptomatic, moderately symptomatic. No respondents had acquired
immunodeficiency syndrome at baseline (see text). RR indicates risk ratio; CI, confidence interval; minus sign, negative; and plus sign, positive.
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Table 3. Baseline Characteristics of Fully Employed Seronegative and Asymptomatic HIV+ Respondents in the Columbia Cohort*





























































* Neuropsychologic performance (NP) global score assesses defective performance in neuropsychologic domains based on age- and education-adjusted
norms (range, 0 to 4, with 4 indicating defective performance [z<2] in memory and two other domains; see Stern et ai3). Neurologic rating is an overall
symptom index based on neurologic examination of motor, behavior, and cognitive performance. Motor and cognitive functions are subscales of the overall
index. High scores indicate poorer function. Diagnosis of depressive and substance abuse disorders (alcohol and illicit drugs) is based on DSM-III-R criteria.
The disability scale is an expanded version of the Kurtzke Disability Scale (Kurtzke15). The social class scale is Hollinghead's revised version, with scores
ranging from 1 (menial) to 9 (professional). HIV+ indicates human immunodeficiency virus positive.
Table 4. Cumulative Incidence of Work Disability Among Seronegative and Asymptomatic WV+ Respondents
According to Time-Dependent Neuropsychologic Status*
Group  Cumulative Incidence Censored, % Beta Estimate RR 95% CI
HIV-, NP normal 60 0.15 0.90
...
1.00
HIV-, NP defective 12 0.25 0.10 0.665 1.95 0.4-9.6
HIV+, asymptomatic, NP normal 36 0.30 0.27 0.792 2.21 0.8-6.2
HIV+, asymptomatic, NP defective 8 0.75 0.25 2.147 8.47 2.7-26.5
* Defective neuropsychologic performance (NP) defined as defective scores (is2, for age- and education-adjusted norms) in two or more domains (Stern
et al3). This measure of defective NP performance was introduced as a time-dependent covariate in the Cox proportional hazards regression model. HIV
indicates human immunodeficiency virus; minus sign, negative; plus sign, positive; RR, risk ratio; and CI, confidence interval.
disability. This analysis showed that neuropsychologic
deficit in a subset of the asymptomatic HIV+ subjects is
responsible for the elevated risk of work disability.
Table 4 presents this finding in detail.
Table 4 divides seronegative and asymptomatic
HIV+ subjects according to whether subjects demon¬
strated defective neuropsychologic performance during
the follow-up period. As shown in Table 4, asymptom¬
atic HIV+ subjects who scored in the normal range of
neuropsychologic performance did not have a signifi¬
cantly elevated risk of work disability (RR, 2.21; 95% CI,
0.8 to 6.2); unity is included in the CI. Only those with
defective neuropsychologic performance had a signifi¬
cantly elevated RR of 8.47 (95% CI, 2.7 to 26.5); 18.2%(8/44) of the initially asymptomatic HIV+ subjects ex¬
perienced neuropsychologic impairment in the course of
follow-up, and 75% (6/8) of these subjects also experi¬
enced work disability. Of the 36 subjects who did not de¬
velop neuropsychologic impairment, nine experienced
work disability (cumulative incidence of 30%).
It is worth noting that the proportion of subjects who
scored in the defective range of neuropsychologic perfor¬
mance at any assessment did not significantly differ be¬
tween seronegative and seropositive subjects; for ex¬
ample, 16.7% (12/72) of the seronegative subjects had at
least one assessment with a score in the defective range.
However, seropositive subjects who scored in the defec¬
tive range at a particular visit were likely to score in the
defective range at subsequent visits as well, while defec¬
tive performance in seronegative subjects was "sporadic,"
ie, more variable across visits. Also, for asymptomatic HIV4-
subjects, defective performance was a predictor of inci¬
dent work disability (as indicated by the significantly el¬
evated RR); for seronegative subjects, it was not.
The association between neuropsychologic deficit
and work disability in the initially asymptomatic sub¬jects may reflect the progress of systemic disease, rather
than an independent predictive significance for neuro¬
psychologic impairment. To assess this possibility, the
number of HIV-related symptoms was entered as a time-
dependent covariate; this allows the influence of pro¬
gressive systemic disease to be assessed relative to neu¬
ropsychologic impairment in predicting incident work
disability. As shown in Table 5, such adjustment did
not reduce the predictive significance of neuropsycho¬
logic impairment, nor did additional adjustment for base¬
line CD4+ cells and neurologic rating. The adjusted RR
for subjects initially asymptomatic who developed neu¬
ropsychologic deficits was 5.47 (95% CI, 1.08 to 27.7).
Repeating the analysis for the CD4+ cell count as a time-
dependent covariate showed similar results. Even with such
adjustment, asymptomatic subjects who developed neuro¬
psychologic deficit showed a significantly increased risk of
work disability (RR, 4.69; 95% CI, 1.04 to 21.14). Seroposi¬
tive subjects who failed to develop neuropsychologic defi¬
cits did not show a significantly elevated risk.
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Table 5. Work Disability Risk Ratios for HIV Status
and NP Impairment Adjusted for Covariates: Final Model(Time-Dependent Symptom Stage, Baseline Neurologic
Symptom Status, Baseline CD4>)
Beta
Group  Estimate RR 95% CI
HIV-, NP normal 60
...
1.00
HIV-, NP defective 12 0.664 1.89 0.38-9.4
HIV+, asymptomatic,
NP normal 36 0.403 1.50 0.37-6.1
HIV+, asymptomatic,
NP defective 8 1.70 5.47 1.08-27.7
*HIV indicates human immunodeficiency virus; minus sign, negative;
plus sign, positive; NP, neuropsychologic performance; RR, risk ratio; and
CI, confidence interval.
These results show that incident neuropsychologic
deficit in this group of initially asymptomatic seroposi¬
tive men predicts work disability, even taking into ac¬
count the worsening symptom stage and the CD4+ cell
count over time. Table 6 shows this result in an alter¬
native format. The table is limited to subjects initially
asymptomatic and shows the percentage remaining
asymptomatic at the time ofwork disability (or at the last
follow-up for those not reaching the disability end point),
cross-classified by neuropsychologic status.
After 4.5 years of follow-up, 27% (12/44) of the ini¬
tially asymptomatic men remained asymptomatic. The pro¬
portion ofsubjects who remained asymptomatic was not
significantly different among the four groups defined by
incidentwork disability and neuropsychologic status. More
specifically, among subjects experiencing work disabil¬
ity, those with and without defective neuropsychologic
performance did not significantly differ in the proportion
remaining asymptomatic (33% and 44%, respectively). Simi¬
lar results were obtained for the proportions of subjects
with CD4+ cell counts below 0.20X 107L (200/µ 3).
Finally, in the baseline asymptomatic group, work
disability was not associated with psychiatric diagnosis.
Depressive disorders were equally distributed between sub-jects who experienced work disability and those who did
not (13.3% and 13.8%, respectively). Substance abuse di¬
agnoses were higher in the group that remained employed.
COMMENT
This research has shown that baseline asymptomatic HIV4-
status is associated with increased risk of work disability,
relative to seronegative control subjects, over a 4.5-year fol¬
low-up period. This increased risk is largely the result of a
much higher risk among a subset of asymptomatic HIV 4-
subjects who go on to develop severe neuropsychologic
symptoms in the course of infection. These subjects are also
at increased risk of mortality, for in this cohort half (four
of eight) are known to have died by the 10th assessment.
This confirms the findings of Mayeux et al,10 who found
that defective neuropsychologic performance in HIV in¬
fection was associated with increased risk of mortality.
At baseline, asymptomatic HIV+ subjects who went
on to experience neuropsychologic deficit and work dis¬
ability did not differ in obvious ways from other asymp-
Table 6. Incident Neuropsychologic Deficit and Work
Disability Among Subjects Asymptomatic at Baseline:
Proportion Remaining Asymptomatic at Time of Disability
or Last Follow-up'
Baseline HIV+ Asymptomatic Subjects (N=44)
 -1
With Incident Remaining
Neuropsychologic With Incident Work Asymptomatic,
Deficit, No. Disability, No. No. (%)
Yes, 8
No, 36
 Yes, 6 2 (33)L No, 2 0 (0)
 Yes, 9 4 (44)L No, 27 6 (22)
*F resi for asymptomatic status (analysis of variance) is not significant.
HIV+ indicates human immunodeficiency virus positive.
tomatic seropositive subjects. The two groups did not dif¬
fer significantly in CD4+ cell counts, in neurologic sta¬
tus, or in medical status. However, subjects who later
experienced work disability already showed significantly
poorer performance at baseline on a variety of neuropsy¬
chologic tests (data available on request), including raw
score differences in verbal memory (selective reminding,
delayed recall), language (controlled verbal fluency, ani¬
mal recognition), motor function (Trails- , Purdue peg-
board) , and attention (cancellations, digit span forward
and backward). Thus, poor neuropsychologic performance
during the phase of asymptomatic HIV infection may in¬
dicate increased risk of early functional morbidity.
The significance of defective neuropsychologic per¬
formance as a source of work disability in asymptomatic
subjects is confirmed in proportional hazards models that
adjust for competing sources of work disability, such as
worsening symptom status and worsening CD4+ cell sta¬
tus. Adjusting for these covariates showed that defective
neuropsychologic performance in the course of HIV in¬
fection still significantly increased the risk of work dis¬
ability, relative to seronegative, neuropsychologically nor¬
mal control subjects.
These findings suggest that only a subset of asymp¬
tomatic HtV+ subjects develop severe neuropsycho¬
logic impairment and face an increased risk of incident
work disability; in this cohort, 18.2% (8/44) of the sub¬jects fell into this category. The prevalence of defective
neuropsychologic performance among seronegative sub¬jects (16.7% [12/72])was similar (ie, a similar propor¬
tion overall scored in the defective range at some point
in the course of follow-up); but for these seronegative
subjects, defective neuropsychologic performance was not
sustained over subsequent assessments and was not a sig¬
nificant predictor of work disability.
While the sample size is small, requiring caution in the
interpretation of results, it is notable that seropositivity in¬
creased the risk of work disability among the 20 subjects(12 of 72 seronegative, eight of44 asymptomatic seroposi¬
tive) who showed defective neuropsychologic performance
at follow-up assessments. The cumulative incidence ofwork
disability among seronegative subj ects who developed neu¬
ropsychologic deficits was 25%; but among seropositive sub¬jects in this category, the cumulative incidence was 75%.
Incident neuropsychologic deficit remains a signifi-
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cant predictor ofwork disability, even with adjustment for
progressive systemic disease (as indicated by the number
of HIV-related symptoms and CD4+ cell counts in the
course of infection). This indicates that neuropsycho¬
logic impairment is not simply a surrogate for more ad¬
vanced disease in predicting work disability. Examining
the proportion of subjects still asymptomatic at the point
of disability confirms this result. If more advanced dis¬
ease were responsible for work disability (with no inde¬
pendent effect for defective neuropsychologic status), the
neuropsychologically compromised group should show
a lower proportion of subjects still asymptomatic at the
time of disability. In fact, the proportion of asymptomat¬
ic subjects in the impaired and nonimpaired groups was
not significantly different (two of six vs four of nine). The
proportion remaining asymptomatic was actually some¬
what lower in the group that did not experience neuro¬
psychologic deficit and continued to work (6/27 [22%]).
In these analyses, a stringent definition of work dis¬
ability was employed ; subj ects had to work 20 or less hours
per week for 2 consecutive years ( four follow-up visits) to
be considered an incident case. We chose this duration to
eliminate transient work reduction unrelated to HIV. Be¬
cause this definition excludes short periods ofwork disabil¬
ity (which are clearly significant in the lives ofpeople with
HIV infection), analyses were also conducted with less strin¬
gent definitions of work disability, taking as an end point( 1 ) less than 20 h/wk persisting for only 1 year and (2) first
occurrence of less than 20 h/wk, whatever its duration over
subsequent assessments. Proportional hazards regression
models using these end points yielded similar results.
It should be stressed that the increased risk of work
disabilityassociatedwithasymptomatic HIV infectionwas
evident only in the follow-up period. A baseline compari¬
son of cohort subjects who were working and not work¬
ing did not reveal significant differences in neuropsycho¬
logic performance. Heaton et al19 reported such a baseline
difference, even when limiting the analysis to asympto¬
matic subjects. Lack of such a difference in the Columbia
cohort may be attributable to unemployment linked to eco¬
nomic trends (rather than HIV), onset ofsevere neuropsy¬
chologic impairment at a later point in the course of infec¬
tion, and the generally high economic status of the cohort.
The finding of increased risk of work disability
among asymptomatic HIV+ subjects, relative to that
among seronegative control subjects, should be under¬
stood in the context of certain limitations in this study.
First, we have assessed work disability with a single in¬
dicator, eg, whether subjects are working more or less
than 20 hours a week. It is possible that more sensitive
occupational measures, such as qualitative changes in
work performance, would show greater rates of work dis¬
ability early in the course of HIV infection. Second, while
defective neuropsychologic performance is the best pre¬
dictor of incident work disability in the initially asymp¬
tomatic subjects, we cannot assume that these defects
cause work disability. That is, subjects may still be per¬
forming work duties adequately, but they may quit work¬
ing because of other concerns, such as fear that they will
soon be unable to perform such work duties. The actual
motivations to stop working or remain employed in the
face of HIV-related deficits require further research.
In summary, this research suggests that a subset of
seropositive asymptomatic subjects, for reasons still un¬
clear, is likely to develop neuropsychologic impairment
severe enough to increase their risk ofwork disability. The
relationship between neuropsychologic impairment and
work disability remains even when adjustment is made for
the CD4+ cell count and symptom status at the time of
disability. The prognosis for this pattern of HIV infection
is poor, with increased risk of mortality. Neuropsycho¬
logic tests may, thus, be an important diagnostic tool for
identifying this subset of early, asymptomatic HIV pa¬
tients who need to be targeted for therapies designed to
arrest the neurologic effects of HIV infection.
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